Patents Assigned to Otsuka Pharmaceutical Co., Ltd.
-
Publication number: 20200253251Abstract: The present invention relates to an extract obtained by extracting useful components containing equol from an equol-containing fermented soybean hypocotyl, and to a method for producing the same. The present invention makes it possible to efficiently obtain useful components containing equol from the fermented soybean hypocotyl by subjecting an equol-containing fermented soybean hypocotyl to extraction using an ethanol aqueous solution as an extractant. The present invention reduces the content of saponin, which causes an unpleasant taste, by sequentially subjecting the equol-containing fermented soybean hypocotyl to extraction using an ethanol aqueous solution and ethanol, while efficiently extracting equol and glycitein.Type: ApplicationFiled: April 30, 2020Publication date: August 13, 2020Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Michiaki TOMINAGA, Takao TAKI, Toshiaki MATSUMOTO, Izumi HANYA, Takuma IMADA, Kunihiko MATSUOKA, Takuya KISHIMOTO, Yuko UCHIYAMA, Hiromasa TSUNEISHI, Machiko TSUJI, Tania VALDES-GONZALEZ, Kentaro TADANO, Kyoko KAMEDA
-
Publication number: 20200246335Abstract: The present invention provides a heat shock protein expression-inducing agent, more specifically, a heat shock protein expression-inducing agent comprising a compound represented by formula (I): wherein R is a lower alkyl, phenyl, or hydroxyphenyl, or a salt thereof.Type: ApplicationFiled: April 3, 2020Publication date: August 6, 2020Applicants: AMINO UP CHEMICAL CO., LTD., OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Kazunori GOTO, Jun NAKAHIGASHI, Atsuya SATO, Yosuke HIRAYAMA, Moeri HORIKOSHI, Noriyuki KOUDA, Syoichiro INOUE, Ikutaro SATO, Manami KATO
-
Publication number: 20200246333Abstract: Disclosed are a method for producing an aripiprazole suspension, wherein the aripiprazole has a mean particle size of 1 to 10 ?m, the method comprising the steps of: (a) combining bulk aripiprazole and a vehicle to form a primary suspension; (b) subjecting the primary suspension to first pulverization using e.g., a high shear pulverizing machine, a dispersion machine that applies shear force to a material to be processed, a colloid mill, an ultrasonic dispersion machine, or a high-pressure jet type emulsifying dispersion machine to form a secondary suspension; and (c) subjecting the secondary suspension to second pulverization using e.g., a high-pressure jet type emulsifying dispersion machine to form a sterile final suspension; and a method for producing a freeze-dried formulation from the aripiprazole suspension.Type: ApplicationFiled: December 6, 2019Publication date: August 6, 2020Applicant: Otsuka Pharmaceutical Co., Ltd.Inventors: Shogo Hiraoka, Takakuni Matsuda, Junichi Hatanaka
-
Publication number: 20200237755Abstract: The present invention provides a heterocyclic compound represented by the general formula (1): The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety.Type: ApplicationFiled: April 14, 2020Publication date: July 30, 2020Applicant: Otsuka Pharmaceutical Co., Ltd.Inventors: Hiroshi YAMASHITA, Nobuaki ITO, Shin MIYAMURA, Kunio OSHIMA, Jun MATSUBARA, Hideaki KURODA, Haruka TAKAHASHI, Satoshi SHIMIZU, Tatsuyoshi TANAKA
-
Patent number: 10681930Abstract: The present invention relates to an extract obtained by extracting useful components containing equal from an equol-containing fermented soybean hypocotyl, and to a method for producing the same. The present invention makes it possible to efficiently obtain useful components containing equol from the fermented soybean hypocotyl by subjecting an equol-containing fermented soybean hypocotyl to extraction using an ethanol aqueous solution as an extractant. The present invention reduces the content of saponin, which causes an unpleasant taste, by sequentially subjecting the equal-containing fermented soybean hypocotyl to extraction using an ethanol aqueous solution and ethanol, while efficiently extracting equol and glycitein.Type: GrantFiled: November 9, 2012Date of Patent: June 16, 2020Assignee: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Michiaki Tominaga, Takao Taki, Toshiaki Matsumoto, Izumi Hanya, Takuma Imada, Kunihiko Matsuoka, Takuya Kishimoto, Yuko Uchiyama, Hiromasa Tsuneishi, Machiko Tsuji, Tania Valdes-Gonzalez, Kentaro Tadano, Kyoko Kameda
-
Publication number: 20200179517Abstract: An object of the present invention is to provide a storage-stable injectable preparation comprising a composition comprising a poorly soluble drug as an active ingredient and a dispersion medium. Another object of the present invention is to provide a compact, lightweight prefilled syringe by filling a syringe with the injectable preparation. The present invention provides an injectable preparation comprising a composition comprising a poorly soluble drug, a dispersion medium, and a specific suspending agent, the composition having a viscosity of 40 pascal-seconds or more in at least one point in the shear rate range of 0.01 to 0.02 s?1 and having a viscosity of 0.2 pascal-seconds or less in at least one point in the shear rate range of 900 to 1,000 s?1, as measured.Type: ApplicationFiled: February 7, 2020Publication date: June 11, 2020Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Daiki KANEKO, Takakuni MATSUDA, Yusuke HOSHIKA
-
Publication number: 20200182856Abstract: An aspect of the disclosure provides a method of evaluating the nutriture of a subject, comprising (1) calculating the ratio of the 13CO2 amount to the unlabeled CO2 amount or total CO2 amount in an expired air sample obtained from the subject to which a 13C-labeled amino acid was administered; and (2) comparing the ratio with a reference value to evaluate the nutriture. Another aspect of the disclosure provides a composition comprising a 13C-labeled amino acid for evaluating the nutriture of a subject.Type: ApplicationFiled: November 24, 2017Publication date: June 11, 2020Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Makoto INADA, Keiko KAWATA, Kimiyoshi SUDOU
-
Publication number: 20200181092Abstract: The present invention provides an agent for treating malignant tumor, comprising a compound of formula (1): wherein R1 to R4 are hydrogen atom, halogen, or etc., Y is optionally-substituted alkylene group or etc.Type: ApplicationFiled: February 12, 2020Publication date: June 11, 2020Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Takahiro KATOH, Masatoshi Iida, Yuki Terauchi, Kazuya Yamaguchi, Toshiyuki Hirose, Fumiharu Yokoyama, Hikaru Nishimori, Yutaka Obuchi, Hiroshi Nabeshima, Emiri Takaki
-
Publication number: 20200171006Abstract: An ointment is provided. The ointment stably comprises an oxazole compound that has specific inhibitory activity against PDE4 and that is represented by the following formula (11). The ointment can be efficiently absorbed into the skin.Type: ApplicationFiled: February 5, 2020Publication date: June 4, 2020Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Yoshihiro MURAKAMI, Hitoshi MATSUSHITA, Kengo MATSUMOTO, Minoru OKADA, Yohei YUKI, Noriyuki KOYAMA, Naohiko KANAI
-
Publication number: 20200163960Abstract: An object of the present invention is to provide a sustained-release injectable preparation which is in a medication administration form that can provide the effect of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one for a prolonged period of time, the preparation releasing a therapeutically effective amount of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one for at least one week. The present invention provides an injectable preparation containing 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof as an active ingredient, which releases the active ingredient in such a manner that its blood concentration is maintained for at least one week.Type: ApplicationFiled: January 28, 2020Publication date: May 28, 2020Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Tetsuya SATO, Takuya MINOWA, Yusuke HOSHIKA, Hidekazu TOYOFUKU
-
Publication number: 20200155764Abstract: A dual chamber prefillable syringe (100) includes: a cylinder (10) which has a bypass portion (11); a hub luer-lock (20); a front stopper (30); a middle stopper (40) which seals a preparation (S) together with the front stopper (30); an end stopper (50) which seals a solvent (L) together with the middle stopper (40); a finger grip (60); and a plunger rod (70) which is connected to the end stopper from the rear end side. A female screw portion (64) which is screwed around the axis line is formed on an inner circumferential surface of the finger grip (60), and a male screw portion (73) which is able to be screwed to the female screw portion is formed on an outer circumferential surface of the plunger rod (70).Type: ApplicationFiled: November 15, 2019Publication date: May 21, 2020Applicants: ARTE CORPORATION, OTSUKA PHARMACEUTICAL CO. LTD.Inventors: Makoto KAKIUCHI, Seiji SHIMAZAKI, Yasuhiko TAKESHIMA, Shogo HIRAOKA, Tadayoshi MAESAKA
-
Patent number: 10654892Abstract: The present invention relates to a method for activating helper T cells, which includes the step of activating helper T cells by adding a WT1 peptide to antigen presenting cells, wherein the WT1 peptide has the ability to bind to any MHC class II molecule of an HLA-DRB1*0101 molecule, an HLA-DRB1*0401 molecule, an HLA-DRB1*0403 molecule, an HLA-DRB1*0406 molecule, an HLA-DRB1*0803 molecule, an HLA-DRB1*0901 molecule, an HLA-DRB1*1101 molecule, an HLA-DRB3*0202 molecule, an HLA-DRB4*0101 molecule, an HLA-DPB1*0201 molecule or an HLA-DPB1*0301 molecule, and the like.Type: GrantFiled: October 4, 2011Date of Patent: May 19, 2020Assignees: International Institute of Cancer Immunology, Inc., OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Haruo Sugiyama, Shinji Sogo, Masayoshi Sato, Ryuki Kitamoto, Yoshihiro Goto
-
Publication number: 20200140424Abstract: An object of the present invention is to provide a compound that can be used as a more superior therapeutic agent for central nervous system diseases. The present invention provides a dihydrate of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl) butoxy]-1H-quinolin-2-one or of a salt thereof, and a process for producing the same.Type: ApplicationFiled: September 9, 2019Publication date: May 7, 2020Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Hiroshi YAMASHITA, Tetsuya SATO, Takuya MINOWA, Yusuke HOSHIKA, Hidekazu TOYOFUKU, Tatsuya YAMAGUCHI, Masahiro SOTA, Shuuji KAWANO, Takayuki NAKAMURA, Ryohei ETO, Takuma IKEBUCHI, Kei MORIYAMA, Nobuaki ITO
-
Publication number: 20200128858Abstract: Provided is a method for producing a processed food, in which the generation of a sulfur smell or the imparting of an unpleasant flavor like an accumulated sulfur smell is suppressed. [Means for Resolution] Provided is a method for producing a processed food in which the generation of a sulfur smell is suppressed, including the following steps (A) and (B): (A) a step of bringing a transglutaminase and/or a reducing sugar into contact with a solid food material containing a protein as a main nutritional component; and (B) a step of subjecting the food material after the step (A) to a heat sterilization treatment.Type: ApplicationFiled: July 3, 2017Publication date: April 30, 2020Applicant: EN Otsuka Pharmaceutical Co., Ltd.Inventor: Yuji HONMA
-
Patent number: 10632079Abstract: Disclosed are microspheres having a core/shell structure and a spherical shape, wherein (a) the core comprises solid-state aripiprazole, and (b) the shell coats all or most of the surface of the core, and the shell comprises a biodegradable polymer; a process for producing the microspheres; and an injectable aqueous suspension formulation containing the microspheres; and the like.Type: GrantFiled: June 9, 2008Date of Patent: April 28, 2020Assignee: Otsuka Pharmaceuticals Co., Ltd.Inventor: Shogo Hiraoka
-
Patent number: 10626095Abstract: This invention relates to a cyanotriazole compound represented by the formula (1): wherein each symbols are defined in the specification, or a salt thereof. The compound or a salt thereof stimulates the citric acid cycle activity and/or improves hyperglycemia with less side effects, and excellent safety, and therefore, it is useful for treating and/or preventing diseases or disorders on which citric acid cycle activation and/or improvement of hyperglycemia has a prophylactic and/or therapeutic effect, for example, diabetes, impaired glucose tolerance, insulin resistance, diabetic complications, obesity, dyslipidemia, hepatic steatosis, atherosclerosis and/or cardiovascular disease, as well as diseases or disorders that would benefit from stimulating energy expenditure.Type: GrantFiled: July 16, 2014Date of Patent: April 21, 2020Assignee: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Seiji Sato, Satoshi Matsuda, Chiharu Matsumura, Motohiro Itotani, Toshio Shinohara, Shigekazu Fujita, Yohji Sakurai, Kuninori Tai, Tae Fukushima, Naohide Kanemoto, Takashi Okamoto
-
Patent number: 10624889Abstract: An object of the present invention is to provide a sustained-release injectable preparation which is in a medication administration form that can provide the effect of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one for a prolonged period of time, the preparation releasing a therapeutically effective amount of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one for at least one week. The present invention provides an injectable preparation containing 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof as an active ingredient, which releases the active ingredient in such a manner that its blood concentration is maintained for at least one week.Type: GrantFiled: September 12, 2017Date of Patent: April 21, 2020Assignee: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Tetsuya Sato, Takuya Minowa, Yusuke Hoshika, Hidekazu Toyofuku
-
Patent number: 10611731Abstract: The present invention provides an agent for treating malignant tumor, comprising a compound of formula (1): wherein R1 to R4 are hydrogen atom, halogen, or etc., Y is optionally-substituted alkylene group or etc.Type: GrantFiled: March 2, 2017Date of Patent: April 7, 2020Assignee: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Takahiro Katoh, Masatoshi Iida, Yuki Terauchi, Kazuya Yamaguchi, Toshiyuki Hirose, Fumiharu Yokoyama, Hikaru Nishimori, Yutaka Obuchi, Hiroshi Nabeshima, Emiri Takaki
-
Patent number: 10603331Abstract: A heterocyclic compound represented by the general formula (1) or a salt thereof: wherein m, l, and n respectively represent an integer of 1 or 2; X represents βOβ or βCH2β; R1 represents hydrogen, a lower alkyl group, a hydroxy-lower alkyl group, a protecting group, or a tri-lower alkylsilyloxy-lower alkyl group; R2 and R3, which are the same or different, each independently represent hydrogen or a lower alkyl group; or R2 and R3 are bonded to form a cyclo-C3-C8 alkyl group; and R4 represents an aromatic group or a heterocyclic group, wherein the aromatic or heterocyclic group may have one or more arbitrary substituent(s).Type: GrantFiled: August 30, 2018Date of Patent: March 31, 2020Assignee: Otsuka Pharmaceutical Co., Ltd.Inventors: Nobuaki Ito, Hirofumi Sasaki, Kuninori Tai, Tomoichi Shinohara
-
Patent number: RE48059Abstract: The present invention provides a heterocyclic compound represented by the general formula (1): The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety.Type: GrantFiled: November 16, 2017Date of Patent: June 23, 2020Assignee: Otsuka Pharmaceutical Co., Ltd.Inventors: Hiroshi Yamashita, Nobuaki Ito, Shin Miyamura, Kunio Oshima, Jun Matsubara, Hideaki Kuroda, Haruka Takahashi, Satoshi Shimizu, Tatsuyoshi Tanaka, Yasuo Oshiro, Shinichi Taira